ZA200404294B - Novel benzothiazine and benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same. - Google Patents
Novel benzothiazine and benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same. Download PDFInfo
- Publication number
- ZA200404294B ZA200404294B ZA200404294A ZA200404294A ZA200404294B ZA 200404294 B ZA200404294 B ZA 200404294B ZA 200404294 A ZA200404294 A ZA 200404294A ZA 200404294 A ZA200404294 A ZA 200404294A ZA 200404294 B ZA200404294 B ZA 200404294B
- Authority
- ZA
- South Africa
- Prior art keywords
- formula
- compound
- group
- branched
- linear
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 6
- 150000007658 benzothiadiazines Chemical class 0.000 title description 4
- UJVBZCCNLAAMOV-UHFFFAOYSA-N 2h-1,2-benzothiazine Chemical compound C1=CC=C2C=CNSC2=C1 UJVBZCCNLAAMOV-UHFFFAOYSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 97
- 229910052757 nitrogen Inorganic materials 0.000 claims description 51
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 27
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- 125000005843 halogen group Chemical group 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- -1 cyano, nitro, amino Chemical group 0.000 claims description 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- 230000009471 action Effects 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 14
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000007858 starting material Substances 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 125000002619 bicyclic group Chemical group 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 238000010531 catalytic reduction reaction Methods 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 150000004678 hydrides Chemical class 0.000 claims description 4
- 125000002950 monocyclic group Chemical group 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 4
- 239000012279 sodium borohydride Substances 0.000 claims description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 2
- OSXDHRVFRPBPBH-UHFFFAOYSA-N 7-(3-methylphenoxy)-2,3,3a,4-tetrahydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide Chemical compound CC1=CC=CC(OC=2C=C3S(=O)(=O)NC4CCCN4C3=CC=2)=C1 OSXDHRVFRPBPBH-UHFFFAOYSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 239000005864 Sulphur Substances 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 2
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 150000001409 amidines Chemical class 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 238000010511 deprotection reaction Methods 0.000 claims description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 150000002901 organomagnesium compounds Chemical class 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 230000008707 rearrangement Effects 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 238000006722 reduction reaction Methods 0.000 claims description 2
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 claims 1
- DWMHTHJACVYUAE-UHFFFAOYSA-N 3-[(5,5-dioxo-2,3,3a,4-tetrahydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazin-7-yl)oxy]benzoic acid Chemical compound OC(=O)C1=CC=CC(OC=2C=C3S(=O)(=O)NC4CCCN4C3=CC=2)=C1 DWMHTHJACVYUAE-UHFFFAOYSA-N 0.000 claims 1
- QWAOZSRWNZGEOO-UHFFFAOYSA-N [3-[(5,5-dioxo-2,3,3a,4-tetrahydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazin-7-yl)oxy]phenyl]-ethoxyphosphinic acid Chemical compound CCOP(O)(=O)C1=CC=CC(OC=2C=C3S(=O)(=O)NC4CCCN4C3=CC=2)=C1 QWAOZSRWNZGEOO-UHFFFAOYSA-N 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000002844 melting Methods 0.000 description 47
- 230000008018 melting Effects 0.000 description 47
- 229910052739 hydrogen Inorganic materials 0.000 description 38
- 238000004452 microanalysis Methods 0.000 description 36
- 229910052717 sulfur Inorganic materials 0.000 description 34
- 239000000047 product Substances 0.000 description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000000203 mixture Substances 0.000 description 12
- 238000003756 stirring Methods 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- GZDNYQLUOGPCDR-UHFFFAOYSA-N 7-(3-methoxyphenoxy)-2,3,3a,4-tetrahydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide Chemical compound COC1=CC=CC(OC=2C=C3S(=O)(=O)NC4CCCN4C3=CC=2)=C1 GZDNYQLUOGPCDR-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical group NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- HAVZTGSQJIEKPI-UHFFFAOYSA-N benzothiadiazine Chemical compound C1=CC=C2C=NNSC2=C1 HAVZTGSQJIEKPI-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229940073584 methylene chloride Drugs 0.000 description 3
- 102000003678 AMPA Receptors Human genes 0.000 description 2
- 108090000078 AMPA Receptors Proteins 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QJAFHQBDVJTCCZ-UHFFFAOYSA-N 1,1-dioxo-3,4-dihydro-2h-1$l^{6},2-benzothiazin-7-ol Chemical compound C1CNS(=O)(=O)C2=CC(O)=CC=C21 QJAFHQBDVJTCCZ-UHFFFAOYSA-N 0.000 description 1
- OMYGMZMFNVIPGR-UHFFFAOYSA-N 1-(4-hydroxy-7-methoxy-1,1-dioxo-1$l^{6},2-benzothiazin-2-yl)ethanone Chemical compound OC1=CN(C(C)=O)S(=O)(=O)C2=CC(OC)=CC=C21 OMYGMZMFNVIPGR-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- CSHJCESYHRWFCE-UHFFFAOYSA-N 2-amino-3-hydroxy-2-(5-methyl-1,2-oxazol-4-yl)propanoic acid Chemical compound CC=1ON=CC=1C(N)(CO)C(O)=O CSHJCESYHRWFCE-UHFFFAOYSA-N 0.000 description 1
- RZEDJEWRTBCQKC-UHFFFAOYSA-N 2-amino-3-methoxybenzenesulfonamide Chemical compound COC1=CC=CC(S(N)(=O)=O)=C1N RZEDJEWRTBCQKC-UHFFFAOYSA-N 0.000 description 1
- DSUQOTGCKDGCEZ-UHFFFAOYSA-N 2-amino-5-methoxybenzenesulfonamide Chemical compound COC1=CC=C(N)C(S(N)(=O)=O)=C1 DSUQOTGCKDGCEZ-UHFFFAOYSA-N 0.000 description 1
- IWQUDDNKHBQSBT-UHFFFAOYSA-N 3-[(5,5-dioxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazin-7-yl)oxy]phenol Chemical compound Oc1cccc(Oc2ccc3N4CCCC4NS(=O)(=O)c3c2)c1 IWQUDDNKHBQSBT-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ANPDTGLNEDSYFH-UHFFFAOYSA-N 4-chloro-n-(4-methoxy-2-sulfamoylphenyl)butanamide Chemical compound COC1=CC=C(NC(=O)CCCCl)C(S(N)(=O)=O)=C1 ANPDTGLNEDSYFH-UHFFFAOYSA-N 0.000 description 1
- CDIIZULDSLKBKV-UHFFFAOYSA-N 4-chlorobutanoyl chloride Chemical compound ClCCCC(Cl)=O CDIIZULDSLKBKV-UHFFFAOYSA-N 0.000 description 1
- YDZIJXXRLSATFT-UHFFFAOYSA-N 4-ethyl-7-phenoxy-2,3-dihydro-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C=1C=C2N(CC)CNS(=O)(=O)C2=CC=1OC1=CC=CC=C1 YDZIJXXRLSATFT-UHFFFAOYSA-N 0.000 description 1
- SRQFXWLSYFCBAT-UHFFFAOYSA-N 4-methyl-1,1-dioxo-2,3-dihydro-1$l^{6},2,4-benzothiadiazin-7-ol Chemical compound OC1=CC=C2N(C)CNS(=O)(=O)C2=C1 SRQFXWLSYFCBAT-UHFFFAOYSA-N 0.000 description 1
- ZFVITKPIGVTYEY-UHFFFAOYSA-N 4-methyl-7-phenoxy-2,3-dihydro-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C=1C=C2N(C)CNS(=O)(=O)C2=CC=1OC1=CC=CC=C1 ZFVITKPIGVTYEY-UHFFFAOYSA-N 0.000 description 1
- FGWXGHBHIOINCJ-UHFFFAOYSA-N 6-methoxy-1,1-dioxo-1,2-benzothiazol-3-one Chemical compound COC1=CC=C2C(=O)NS(=O)(=O)C2=C1 FGWXGHBHIOINCJ-UHFFFAOYSA-N 0.000 description 1
- UCVYUTDVIPPNQT-UHFFFAOYSA-N 6-methoxy-1,1-dioxo-2-(2-oxopropyl)-1,2-benzothiazol-3-one Chemical compound COC1=CC=C2C(=O)N(CC(C)=O)S(=O)(=O)C2=C1 UCVYUTDVIPPNQT-UHFFFAOYSA-N 0.000 description 1
- ISLBMCZJJFECOK-UHFFFAOYSA-N 7-(2-methoxyphenoxy)-2,3,3a,4-tetrahydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide Chemical compound COC1=CC=CC=C1OC1=CC=C(N2C(CCC2)NS2(=O)=O)C2=C1 ISLBMCZJJFECOK-UHFFFAOYSA-N 0.000 description 1
- CUTKKHPSBFIFOL-UHFFFAOYSA-N 7-(3-bromophenoxy)-2,3,3a,4-tetrahydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide Chemical compound BrC1=CC=CC(OC=2C=C3S(=O)(=O)NC4CCCN4C3=CC=2)=C1 CUTKKHPSBFIFOL-UHFFFAOYSA-N 0.000 description 1
- LFIRSDNEGXJAMG-UHFFFAOYSA-N 7-(3-ethoxyphenoxy)-2,3,3a,4-tetrahydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide Chemical compound CCOC1=CC=CC(OC=2C=C3S(=O)(=O)NC4CCCN4C3=CC=2)=C1 LFIRSDNEGXJAMG-UHFFFAOYSA-N 0.000 description 1
- MHGMYKXMMQCQTE-UHFFFAOYSA-N 7-(3-ethylphenoxy)-2,3,3a,4-tetrahydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide Chemical compound CCC1=CC=CC(OC=2C=C3S(=O)(=O)NC4CCCN4C3=CC=2)=C1 MHGMYKXMMQCQTE-UHFFFAOYSA-N 0.000 description 1
- KMTRFWWGKPBIPH-UHFFFAOYSA-N 7-(3-fluorophenoxy)-2,3,3a,4-tetrahydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide Chemical compound FC1=CC=CC(OC=2C=C3S(=O)(=O)NC4CCCN4C3=CC=2)=C1 KMTRFWWGKPBIPH-UHFFFAOYSA-N 0.000 description 1
- QJJPLQMRSAWUAW-UHFFFAOYSA-N 7-(3-methylsulfanylphenoxy)-2,3,3a,4-tetrahydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide Chemical compound CSC1=CC=CC(OC=2C=C3S(=O)(=O)NC4CCCN4C3=CC=2)=C1 QJJPLQMRSAWUAW-UHFFFAOYSA-N 0.000 description 1
- VXJUFDLOAZERNF-UHFFFAOYSA-N 7-(3-nitrophenoxy)-2,3,3a,4-tetrahydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide Chemical compound [O-][N+](=O)C1=CC=CC(OC=2C=C3S(=O)(=O)NC4CCCN4C3=CC=2)=C1 VXJUFDLOAZERNF-UHFFFAOYSA-N 0.000 description 1
- UGJCLXMAVBQVRI-UHFFFAOYSA-N 7-(3-phenylmethoxyphenoxy)-2,3,3a,4-tetrahydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide Chemical compound C1=C2S(=O)(=O)NC3CCCN3C2=CC=C1OC(C=1)=CC=CC=1OCC1=CC=CC=C1 UGJCLXMAVBQVRI-UHFFFAOYSA-N 0.000 description 1
- RCLJBWCVEXJFJL-UHFFFAOYSA-N 7-(4-methoxyphenoxy)-2,3,3a,4-tetrahydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide Chemical compound C1=CC(OC)=CC=C1OC1=CC=C(N2C(CCC2)NS2(=O)=O)C2=C1 RCLJBWCVEXJFJL-UHFFFAOYSA-N 0.000 description 1
- SGXKXHOTHGIHOE-UHFFFAOYSA-N 7-(4-methylphenoxy)-2,3,3a,4-tetrahydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide Chemical compound C1=CC(C)=CC=C1OC1=CC=C(N2C(CCC2)NS2(=O)=O)C2=C1 SGXKXHOTHGIHOE-UHFFFAOYSA-N 0.000 description 1
- AYYWCQVDCRMETB-UHFFFAOYSA-N 7-[3-(trifluoromethoxy)phenoxy]-2,3,3a,4-tetrahydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide Chemical compound FC(F)(F)OC1=CC=CC(OC=2C=C3S(=O)(=O)NC4CCCN4C3=CC=2)=C1 AYYWCQVDCRMETB-UHFFFAOYSA-N 0.000 description 1
- QPSSXSMVXPGSHN-UHFFFAOYSA-N 7-[3-(trifluoromethyl)phenoxy]-2,3,3a,4-tetrahydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide Chemical compound FC(F)(F)C1=CC=CC(OC=2C=C3S(=O)(=O)NC4CCCN4C3=CC=2)=C1 QPSSXSMVXPGSHN-UHFFFAOYSA-N 0.000 description 1
- NQLOMTSUVHLJIC-UHFFFAOYSA-N 7-methoxy-4-methyl-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound CN1C=NS(=O)(=O)C2=CC(OC)=CC=C21 NQLOMTSUVHLJIC-UHFFFAOYSA-N 0.000 description 1
- NMODAGHLFPNMTC-UHFFFAOYSA-N 7-methoxy-4-methyl-2,3-dihydro-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound CN1CNS(=O)(=O)C2=CC(OC)=CC=C21 NMODAGHLFPNMTC-UHFFFAOYSA-N 0.000 description 1
- FOGLAAJMVBSRKU-UHFFFAOYSA-N 7-methoxy-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound N1C=NS(=O)(=O)C2=CC(OC)=CC=C21 FOGLAAJMVBSRKU-UHFFFAOYSA-N 0.000 description 1
- CUWYQKNZGDPGOT-UHFFFAOYSA-N 7-phenoxy-2,3,3a,4-tetrahydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide Chemical compound C1=C2S(=O)(=O)NC3CCCN3C2=CC=C1OC1=CC=CC=C1 CUWYQKNZGDPGOT-UHFFFAOYSA-N 0.000 description 1
- RYLCEMUMPNAWDX-UHFFFAOYSA-N 7-phenoxy-3,4-dihydro-2h-1$l^{6},2-benzothiazine 1,1-dioxide Chemical compound C1=C2S(=O)(=O)NCCC2=CC=C1OC1=CC=CC=C1 RYLCEMUMPNAWDX-UHFFFAOYSA-N 0.000 description 1
- NTCIAUOUNYCEQB-UHFFFAOYSA-N 7-phenoxy-4-propyl-2,3-dihydro-1$l^{6},2,4-benzothiadiazine 1,1-dioxide Chemical compound C=1C=C2N(CCC)CNS(=O)(=O)C2=CC=1OC1=CC=CC=C1 NTCIAUOUNYCEQB-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- LPDFMYSOFHOYSN-UHFFFAOYSA-N 8-phenoxy-2,3,3a,4-tetrahydro-1h-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide Chemical compound C=1C=C2S(=O)(=O)NC3CCCN3C2=CC=1OC1=CC=CC=C1 LPDFMYSOFHOYSN-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- NMVVJCLUYUWBSZ-UHFFFAOYSA-N aminomethylideneazanium;chloride Chemical compound Cl.NC=N NMVVJCLUYUWBSZ-UHFFFAOYSA-N 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- ZXNRTKGTQJPIJK-UHFFFAOYSA-N aniracetam Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(=O)CCC1 ZXNRTKGTQJPIJK-UHFFFAOYSA-N 0.000 description 1
- 229960000793 aniracetam Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 150000001543 aryl boronic acids Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WPYMKLBDIGXBTP-VQEHIDDOSA-N benzoic acid Chemical compound OC(=O)C1=CC=C[13CH]=C1 WPYMKLBDIGXBTP-VQEHIDDOSA-N 0.000 description 1
- 125000005620 boronic acid group Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 230000000494 facilitatory effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000008587 neuronal excitability Effects 0.000 description 1
- 230000007996 neuronal plasticity Effects 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000024587 synaptic transmission, glutamatergic Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0116621A FR2833956B1 (fr) | 2001-12-21 | 2001-12-21 | Nouveaux derives de benzothiazine et de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200404294B true ZA200404294B (en) | 2005-06-01 |
Family
ID=8870809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200404294A ZA200404294B (en) | 2001-12-21 | 2004-06-01 | Novel benzothiazine and benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same. |
Country Status (22)
Country | Link |
---|---|
US (1) | US7253161B2 (pt) |
EP (1) | EP1480986A1 (pt) |
JP (1) | JP2005518386A (pt) |
KR (1) | KR100586685B1 (pt) |
CN (1) | CN1289509C (pt) |
AR (1) | AR038028A1 (pt) |
AU (1) | AU2002364674B2 (pt) |
BR (1) | BR0214973A (pt) |
CA (1) | CA2471263A1 (pt) |
EA (1) | EA007227B1 (pt) |
FR (1) | FR2833956B1 (pt) |
GE (1) | GEP20063759B (pt) |
HK (1) | HK1071749A1 (pt) |
HU (1) | HUP0402585A3 (pt) |
MA (1) | MA27090A1 (pt) |
MX (1) | MXPA04005837A (pt) |
NO (1) | NO20042978L (pt) |
NZ (1) | NZ533328A (pt) |
PL (1) | PL370159A1 (pt) |
UA (1) | UA77737C2 (pt) |
WO (1) | WO2003053979A1 (pt) |
ZA (1) | ZA200404294B (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2856065B1 (fr) * | 2003-06-13 | 2005-08-19 | Servier Lab | Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
FR2856064B1 (fr) * | 2003-06-13 | 2005-08-19 | Servier Lab | Nouveaux derives de benzothiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
FR2877338B1 (fr) * | 2004-11-03 | 2007-01-26 | Servier Lab | Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR2877342B1 (fr) * | 2004-11-03 | 2007-01-26 | Servier Lab | Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR2879201B1 (fr) * | 2004-12-10 | 2007-02-16 | Servier Lab | Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR2955106B1 (fr) * | 2010-01-08 | 2011-12-23 | Servier Lab | Nouveaux derives de benzothiadiazines cyclopropylees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2013118845A1 (ja) * | 2012-02-08 | 2013-08-15 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
WO2019070044A1 (ja) | 2017-10-06 | 2019-04-11 | 武田薬品工業株式会社 | 複素環化合物 |
CN107641197B (zh) * | 2017-10-30 | 2019-11-22 | 河南工程学院 | 一种以二氧化碳与环氧环己烷为单体的共聚反应催化剂 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2722502B1 (fr) * | 1994-07-12 | 1996-08-23 | Adir | Nouveau derive de benzothiadiazine, son procede depreparation et les compositions pharmaceutiques qui le contiennent |
PL342843A1 (en) * | 1998-02-18 | 2001-07-16 | Neurosearch As | Novel compounds and their use as positive ampa receptor modulators |
FR2812291B1 (fr) * | 2000-07-28 | 2002-12-13 | Adir | Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2001
- 2001-12-21 FR FR0116621A patent/FR2833956B1/fr not_active Expired - Fee Related
-
2002
- 2002-12-18 AR ARP020104932A patent/AR038028A1/es unknown
- 2002-12-20 PL PL02370159A patent/PL370159A1/xx not_active Application Discontinuation
- 2002-12-20 GE GE5645A patent/GEP20063759B/en unknown
- 2002-12-20 JP JP2003554695A patent/JP2005518386A/ja active Pending
- 2002-12-20 KR KR1020047009302A patent/KR100586685B1/ko not_active IP Right Cessation
- 2002-12-20 WO PCT/FR2002/004485 patent/WO2003053979A1/fr active Application Filing
- 2002-12-20 CN CNB028258126A patent/CN1289509C/zh not_active Expired - Fee Related
- 2002-12-20 US US10/498,948 patent/US7253161B2/en not_active Expired - Fee Related
- 2002-12-20 HU HU0402585A patent/HUP0402585A3/hu unknown
- 2002-12-20 EA EA200400758A patent/EA007227B1/ru not_active IP Right Cessation
- 2002-12-20 AU AU2002364674A patent/AU2002364674B2/en not_active Ceased
- 2002-12-20 BR BR0214973-7A patent/BR0214973A/pt not_active IP Right Cessation
- 2002-12-20 MX MXPA04005837A patent/MXPA04005837A/es active IP Right Grant
- 2002-12-20 NZ NZ533328A patent/NZ533328A/en unknown
- 2002-12-20 EP EP02805408A patent/EP1480986A1/fr not_active Withdrawn
- 2002-12-20 CA CA002471263A patent/CA2471263A1/fr not_active Abandoned
- 2002-12-20 UA UA20040706011A patent/UA77737C2/uk unknown
-
2004
- 2004-06-01 ZA ZA200404294A patent/ZA200404294B/en unknown
- 2004-06-04 MA MA27719A patent/MA27090A1/fr unknown
- 2004-07-14 NO NO20042978A patent/NO20042978L/no not_active Application Discontinuation
-
2005
- 2005-05-30 HK HK05104494A patent/HK1071749A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
GEP20063759B (en) | 2006-02-27 |
HUP0402585A3 (en) | 2009-01-28 |
NO20042978L (no) | 2004-07-14 |
EP1480986A1 (fr) | 2004-12-01 |
KR20040073480A (ko) | 2004-08-19 |
FR2833956B1 (fr) | 2004-01-30 |
CN1289509C (zh) | 2006-12-13 |
MXPA04005837A (es) | 2004-09-10 |
JP2005518386A (ja) | 2005-06-23 |
NZ533328A (en) | 2006-10-27 |
US20050124606A1 (en) | 2005-06-09 |
US7253161B2 (en) | 2007-08-07 |
PL370159A1 (en) | 2005-05-16 |
EA007227B1 (ru) | 2006-08-25 |
BR0214973A (pt) | 2004-12-14 |
HUP0402585A2 (hu) | 2005-03-29 |
UA77737C2 (en) | 2007-01-15 |
CN1606560A (zh) | 2005-04-13 |
EA200400758A1 (ru) | 2005-06-30 |
AR038028A1 (es) | 2004-12-22 |
FR2833956A1 (fr) | 2003-06-27 |
AU2002364674B2 (en) | 2007-11-22 |
MA27090A1 (fr) | 2004-12-20 |
CA2471263A1 (fr) | 2003-07-03 |
WO2003053979A1 (fr) | 2003-07-03 |
AU2002364674A1 (en) | 2003-07-09 |
HK1071749A1 (en) | 2005-07-29 |
KR100586685B1 (ko) | 2006-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200404294B (en) | Novel benzothiazine and benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same. | |
US7423034B2 (en) | Benzothiazine and benzothiadiazine compounds | |
AU2005229698A1 (en) | New benzothiadiazine compounds, a process for their preparation and pharmaceutical compositions containing them | |
AU2002365017B2 (en) | Benzothia(DIA)zine derivatives and their use as AMPA modulators | |
KR100645142B1 (ko) | 벤조티아진 및 벤조티아디아진 화합물, 이를 제조하는방법 및 이를 함유하는 약제 조성물 | |
KR100586684B1 (ko) | 벤조티아진 및 벤조티아디아진 유도체, 이의 제조 방법 및이를 함유하는 약제 조성물 |